viewPressure BioSciences, Inc.

Pressure BioSciences's PCT platform featured in more than 20 scientific articles for second year in a row

Articles highlighted the pressure cycling technology's applications in cancer research, food safety and proteomics

Doctor holding a book
'We are particularly pleased that several publications described protocols for combining the PCT platform with existing technologies,' Global Director of Sales & Marketing Roxana McCloskey said

Pressure BioSciences Inc (OTCMKTS:PBIO) announced Thursday that in 2019 — for the second year in a row — more than 20 scientific journal articles were published that highlight the benefits of its patented pressure cycling technology (PCT) platform. 

"PCT-related scientific papers published in 2019 highlighted new and/or improved applications of the PCT platform in a number of important and exciting areas of research, including cancer, food safety, and proteomics,”  Global Director of Sales & Marketing Roxana McCloskey said in a statement. 

“We are particularly pleased that several publications described protocols for combining the PCT platform with existing technologies from other companies to fill a significant unmet need for high throughput protein processing of cancer biopsy tissues."

READ: Pressure BioSciences sees soaring consumables sales in third quarter, projects revenue growth in 2020

Several publications described the use of the PCT platform to rapidly release molecules for analysis from tissue samples, which can be used to achieve a better understanding of patients’ cancers, disease progression and treatment options.

Regarding food, journals highlighted applications using PBI's ultra-high-pressure HUB instrument system for killing food borne bacteria. The company said it believes articles in that vein will increase sales of PCT Systems in the food safety industry.

Additionally, papers reported on the PCT’s use in proteomic research, which covers proteins made or modified by an organism. Studies of proteins using PBI's high pressure PCT platform included protein structure, drug delivery, and disease states, the company said. 

The goal is to reach routine use of the PCT platform in clinical diagnostics and precision medicine.

“We are pleased that the number of PCT-related publications in 2019 exceeded 20 for the second year in a row,” CEO Richard Schumacher said. “We are also pleased with the wide range of applications highlighted in the publications, as these applications fulfill needs in many large and growing markets.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Pressure BioSciences, Inc.

Price: 1.5 USD

Market: OTCQB
Market Cap: $5.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...


Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

2 min read